Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovaBay Pharmaceuticals, Inc. Common Stock (NY:NBY)

1.150 -0.030 (-2.54%)
Official Closing Price Updated: 8:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovaBay Pharmaceuticals, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
NovaBay Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, NovaBay Pharmaceuticals (AMEX:NBY) reported Q2 sales of $2.13 million. Earnings fell to a loss of $1.86 million, resulting in a 22.3% decrease from last... 
Via Benzinga
NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of DERMAdoctor
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Acquires Skincare-Focused Firm For $15M
NovaBay Pharmaceuticals Inc (NYSE: NBY) has agreed to acquire DERMAdoctor LLC, a privately-held company that commercializes dermatologist-developed skincare... 
Via Benzinga
NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Distribute Zocular® Dry Eye Products
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Second Quarter 2021 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
NovaBay Pharmaceuticals to Hold Second Quarter 2021 Conference Call on August 12
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
21 Stocks Moving in Monday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive collaboration agreement to research, develop, and... 
Via Benzinga
NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Participate in Two July Investment Conferences
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Launches First of Several New Products to Expand Avenova Line
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2021 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
NovaBay Pharmaceuticals to Hold First Quarter 2021 Conference Call on May 6
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.